Form 4: Neuronetics Director Megan Rosengarten Acquires 25,000 Restricted Stock Units
SEC Form 4 Filing
Neuronetics Director Megan Rosengarten reports the acquisition of 25,000 restricted stock units (RSUs) in a recent SEC filing.
Summary
- Megan Rosengarten, a director at Neuronetics, Inc. (STIM), acquired 25,000 restricted stock units on May 30, 2024.
- These RSUs vest on the earlier of May 30, 2025, or her Board-approved separation of service from the Issuer, subject to continuous service.
- Each RSU represents a contingent right to receive one share of Neuronetics' common stock.
- Following the transaction, Rosengarten directly owns 110,890 shares of common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of an equity grant, which is generally viewed as a positive sign of aligning director interests with shareholders, but it doesn't inherently indicate strong positive or negative sentiment.
Positives
- The acquisition of RSUs by a director signals confidence in the company's future.
Future Outlook
The vesting of the RSUs is contingent upon continued service, aligning the director's interests with the company's long-term performance.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates a grant of equity compensation to a director, which is a common practice.
Comparison to Industry Standards
- Equity compensation for directors is a standard practice across publicly traded companies to align their interests with shareholders.
- The size and vesting schedule of the RSU grant would need to be compared to similar companies in the medical device industry to assess its competitiveness.
- Companies like Medtronic, Boston Scientific, and Abbott often use similar equity-based compensation for their directors.
Stakeholder Impact
- Shareholders may view the RSU grant as a positive sign, aligning the director's interests with the company's performance.
- Employees may see this as a standard part of executive compensation.
Key Dates
| Date | Description |
|---|---|
| 04/01/2024 | Date of Power of Attorney execution by Megan Rosengarten. |
| 05/30/2024 | Date of the transaction where Megan Rosengarten acquired 25,000 restricted stock units. |
| 05/30/2025 | Vesting date of the restricted stock units, contingent on continuous service. |
| 06/05/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.